Search Items: LEUKEMIA, MYELOID, ACUTE - DRUG THERAPY, GENETICS , . hits: 4
Moujalled, DM; Brown, FC; Chua, CC; Dengler, MA; Pomilio, G; Anstee, NS; Litalien, V; Thompson, E; Morley, T; MacRaild, S; Tiong, IS; Morris, R; Dun, K; Zordan, A; Shah, J; Banquet, S; Halilovic, E; Morris, E; Herold, MJ; Lessene, G; Adams, JM; Huang, DCS; Roberts, AW; Blombery, P; Wei, AH
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
Blood. 2023; 141(6):634-644
Doi: 10.1182/blood.2022016090
Web of Science
PubMed
FullText
FullText_MUG
Thomas, D; Wu, M; Nakauchi, Y; Zheng, M; Thompson-Peach, CAL; Lim, K; Landberg, N; Köhnke, T; Robinson, N; Kaur, S; Kutyna, M; Stafford, M; Hiwase, D; Reinisch, A; Peltz, G; Majeti, R
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
Cancer Discov. 2023; 13(2):496-515
Doi: 10.1158/2159-8290.CD-21-0218
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Zebisch, A; Sill, H
How do non-coding RNAs impact treatment regimens currently being used in AML?
Expert Rev Anticancer Ther. 2022; 22(4):331-333
Doi: 10.1080/14737140.2022.2049764
Web of Science
PubMed
FullText
FullText_MUG
Carlet, M; Völse, K; Vergalli, J; Becker, M; Herold, T; Arner, A; Senft, D; Jurinovic, V; Liu, WH; Gao, Y; Dill, V; Fehse, B; Baldus, CD; Bastian, L; Lenk, L; Schewe, DM; Bagnoli, JW; Vick, B; Schmid, JP; Wilhelm, A; Marschalek, R; Jost, PJ; Miething, C; Riecken, K; Schmidt-Supprian, M; Binder, V; Jeremias, I
In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets.
Nat Commun. 2021; 12(1): 5655
Doi: 10.1038/s41467-021-25963-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG